5 Small-Caps Under Spotlight – CP1, AO1, ZYB, LCM and AGR

Sometimes the small caps stocks can provide tremendous returns and with a mix of diversified small caps, one can also reduce the risk they carry. Here are some of the stocks discussed under the small cap category.

CANNPAL ANIMAL THERAPEUTICS LIMITED (ASX: CP1) – The Company has an available cash balance of $5.11 million and reported a significant increase over June 30, 2017 period of $754,188 and no debt facility. The EPS is negative -0.020 AUD with profit not coming up to the expected levels. No dividends have been paid by the Company or declared by the directors since the commencement of the financial year ended 30 June 2018. CannPal’s lead product is at the forefront of the fast-growing pain treatment market which is worth over US $1bn per annum. As at October 5, 2018 the stock of CannPal’s Limited traded at a market price of $0.160 and has seen a percentage change of -41.30% over the last six months period.

ASSETOWL LIMITED (ASX: AO1) – The company saw a revenue of A$ 13,210 for the period ending June 30, 2018. For the same period, net loss for the year increased from A$ 1.4 million to A$ 3.4 million which is a substantial loss. Resulting into a decline in cents per share (CPS) from A$ 3.16 to A$ 5.22 in 1H 2018. As at June 30, 2018 the company had cash and cash equivalents of $310,651 with zero debt facility. The Company’s total Other Income is $1,009,859, including interest received during the year. As at October 5, 2018 the stock of Assetowl traded at a market price of $0.034 and has seen a percentage change of -59.34% over the last six months period.  

ZYBER HOLDINGS LIMITED (ASX: ZYB) – This year’s consolidated statement of comprehensive income against AUD 2,067,229 in 2017 showed a net loss of AUD 845,808 in 2018. Net cash used in operating activities compared to AUD 1,847,742 a year ago, was AUD 775,495. No dividends have been paid or declared since the start of the period and the directors do not recommend the payment of a dividend in respect of the period. A lot of new executives have been appointed into the company this year which brings in a fresh force of a quality personnel. Cash and cash equivalents at end of financial year stands at $1.001 million with zero or no debt facility. As at October 5, 2018 the stock of Zyber traded at a market price of $0.017 and has seen a percentage change of 71.43% over the last one-year period.

LOGICAMMS LIMITED (ASX: LCM) – The company incurred a loss after tax of $0.8 million for FY18, reduced from a loss of $23.6 million in the previous financial year, compared to $81.1 million for FY17, revenue remained steady at $81.8 million. Compared to a loss of $8.1 million in 2016-17. The Company reported earnings before interest, depreciation, amortization and impairment (EBITDAI) of $1.84 million. It also reported annualized FY18 cost savings of $10.5 million after FY17 restructuring. The Board has elected not to declare a dividend for the year ended 30 June 2018 and believes that reinvesting will lead to better results. As at October 5, 2018 the stock of Logicamms traded at a market price of $0.180 and has seen a percentage change of -44.64% over the last one-year period.

AGUIA RESOURCES LIMITED (ASX: AGR) – The loss for the group after providing for income tax amounted to $2,242,991 in 2018 which lowered from 30 June 2017 of $4,065,149. There were no dividends paid, recommended or declared during the current or previous financial year. Cash and cash equivalents at the end of the financial year stands at $3.405 million with practically no debt or contingent liabilities. Total Revenue is projected at US$1.65 billion, generating EBITDA of US$1.08 billion. They have a successful track record as demonstrated in the financial year 2018 ($9.5 million), 2017 ($14.9 million), 2016 ($9.5 million) and 2015 ($3.8 million) to raise capital. As at October 5, 2018 the stock of Aguia traded at a market price of $0.160 and has seen a percentage change of -66.25% over the last one-year period.

Sponsored ad by Kalkine

stock price

Stock Price movements for CP1, AO1, ZYB, LCM, AGR; Source: Thomson Reuters.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

 

Facebook Comments

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here